Altered pharmacokinetics of ceftazidime in critically ill patients

Antimicrobial Agents and Chemotherapy

Volumn 43, Issue 7, 1999, Pages 1798-1802

  Gomez C M H ^a   Cordingly, J J ^a,b   Palazzo, M G A ^a  

^a CHARING CROSS HOSPITAL   (United Kingdom)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTAZIDIME;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CRITICAL ILLNESS; DISTRIBUTION VOLUME; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG HALF LIFE; EDEMA; EXTRACELLULAR FLUID; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; STEADY STATE;

EID: 0344483897     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/aac.43.7.1798     Document Type: Article

References (29)

1. Ayrton, J. 1981. Assay of ceftazidime in biological fluids using high pressure liquid chromatography. J. Antimicrob. Chemother. 8(Suppl. B):227-231.
2. 1a. Archer, G. L., and R. E. Polk. 1994. Treatment and prophylaxis of bacterial infections. In K. J. Isselbacher, E. Braunwald, J. D. Wilson, J. B. Martin, A. S. Fauci, and D. L. Kasper (ed.), Harrison's principles of internal medicine. McGraw Hill Inc, New York, N.Y.
3. Bakker Woudenberg, I. A., and R. Roosendaal. 1990. Impact of dosage schedule of antibiotics on the treatment of serious infections. Intensive Care Med. 16:S229-S234.
4. Benko, A. S., D. M. Cappelletty, J. A. Kruse, and M. J. Rybak. 1996. Continuous infusion versus intermittent administration of ceftazidime in critically ill patients with suspected gram-negative infections. Antimicrob. Agents Chemother. 40:691-695.
5. Bone, R. C. 1991. The pathogenesis of sepsis. Ann. Intern. Med. 115:457-469.
6. Craig, W. A. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26:1-12.
7. Craig, W. A., and S. C. Ebert. 1992. Continuous infusion of beta-lactam antibiotics. Antimicrob. Agents Chemother. 36:2577-2583.
8. Craig, W. A., and S. Gudmundsson. 1996. Postantibiotic effect, p. 314-316. In V. Lorian (ed.), Antibiotics in laboratory medicine, 4th ed. Williams & Wilkins Co., Baltimore, Md.
9. Drusano, G. L. 1988. Role of pharmacokinetics in the outcome of infections. Antimicrob. Agents Chemother. 32:289-297.
10. Fantin, B., R. Farinotti, A. Thabaut, and C. Carbon. 1994. Conditions for the emergence of resistance to cefpirome and ceftazidime in experimental endocarditis due to Pseudomonas aeruginosa. J. Antimicrob. Chemother. 33: 563-569.
11. Gibaldi, M., and D. Perrier. 1989. Pharmacokinetics. Marcel Dekker, New York, N.Y.
12. Glauser, M. P., G. Zanetti, J. D. Baumgartner, and J. Cohen. 1991. Septic shock: pathogenesis. Lancet 338:732-735.
13. Greenblatt, D. J., and J. Koch-Weser. 1975. Clinical pharmacokinetics. N. Engl. J. Med. 293:702-705.
14. Hanberger, H., L. E. Nilsson, M. Nilsson, and R. Maller. 1991. Post-antibiotic effect (PAE) of beta-lactam antibiotics on gram-negative bacteria in relation to morphology, initial killing and MIC. Eur. J. Clin. Microbiol. Infect. Dis. 10:927-934.
15. Harding, S. M., J. Ayrton, J. E. Thornton, A. J. Munroe, and M. I. J. Hogg. 1981. Pharmacokinetics of ceftazidime in normal subjects. J. Antimicrob. Chemother. 8(Suppl. B):261-262.
16. Harding, S. M., and P. B. Harper. 1983. The pharmacokinetic behaviour of ceftazidime in man and the relationship between serum levels and the in vitro susceptibility of clinical isolates. Infection 11:S49-S53.
17. Hatano, K., Y. Wakai, Y. Watanabe, and Y. Mine. 1994. Simulation of human plasma levels of beta-lactams in mice by multiple dosing and the relationship between the therapeutic efficacy and pharmacodynamic parameters. Chemotherapy 40:1-7.
18. Knaus, W. A., E. A. Draper, D. P. Wagner, and J. E. Zimmerman. 1985. APACHE II: a severity of disease classification system. Crit. Care Med. 13:818-829.
19. Leroy, A., F. Leguy, F. Borsa, G. R. Spencer, J. P. Fillastre, and G. Humbert 1984. Pharmacokinetics of ceftazidime in normal and uremic subjects. Antimicrob. Agents Chemother. 25:638-642.
20. Mouton, J. W., and J. G. den Hollander. 1994. Killing of Pseudomonas aemginosa during continuous and intermittent infusion of ceftazidime in an in vitro pharmacokinetic model. Antimicrob. Agents Chemother. 38:931-936.
21. O'Callaghan, C. H., P. Acred, P. B. Harper, D. M. Ryan, S. M. Kirby, and S. M. Harding. 1980. GR 20263, a new broad-spectrum cephalosporin with anti-pseudomonal activity. Antimicrob. Agents Chemother. 17:876-883.
22. Tipper, D. J., and J. L. Strominger. 1965. Mechanism of action of penicillin: a proposal based on their structural similarity to acyl-D-alanyl-D-alanine. Proc. Natl. Acad. Sci. USA 54:1133-1141.
23. Verbist, L., and J. Verhaegen. 1980. GR-20263: a new aminothiazolyl cephalosporin with high activity against Pseudomonas and Enterobacteriaceae. Antimicrob. Agents Chemother. 17:807-812.
24. Vogelman, B., S. Gudmundsson, J. Leggett, J. Turnidge, S. Ebert, and W. A. Craig. 1988. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J. Infect. Dis. 158:831-847.
25. Waxman, D. J., and J. L. Strominger. 1983. Penicillin-binding proteins and the mechanism of action of beta-lactam antibiotics. Annu. Rev. Biochem. 52:825-869.
26. Wiedemann, B., and H. Grimm. 1996. Susceptibility to antibiotics: species incidence and trends. In V. Lorian (ed.), Antibiotics in laboratory medicine. Williams & Wilkins, Baltimore, Md.
27. Wise, R., J. M. Andrews, and K. A. Bedford. 1980. Comparison of in vitro activity of GR 20263, a novel cephalosporin derivative, with activities of other beta-lactam compounds. Antimicrob. Agents Chemother. 17:884-889.
28. Wise, R., G. C. Armstrong, R. M. Brown, and J. M. Andrews. 1981. The pharmacokinetics and tissue penetration of ceftazidime and cefmandole in healthy volunteers. J. Antimicrob. Chemother. 8(Suppl. B):277-282.
29. Young, R. J., J. Lipman, T. Gin, C. D. Gomersall, G. M. Joynt, and T. E. Oh. 1997. Intermittent bolus dosing of ceftazidime in critically ill patients. J. Antimicrob. Chemother. 40:269-273.